x

Home

Patient Site
Order Form
EpicCare® Link™ Provider Portal
FAQs
Important Risk Information
Contact Us

CRC Screening Unmet Need
About Cologuard
Coverage and Support
Resources and Events

Colorectal cancer (CRC) remains “the most preventable, yet least prevented, cancer.”¹

~53,000

ESTIMATED CRC DEATHS IN 2022²

CRC is the second deadliest cancer after lung cancer²

~150,000

ESTIMATED NEW CRC CASES IN 2022²

That is approximately 400 new CRC diagnoses each day²*

~44 MILLION

AVERAGE-RISK PATIENTS AGED 45 AND OLDER REMAIN ELIGIBLE FOR CRC SCREENING.^3†

National CRC screening rates remain well below established goals^4,5

The time to screen is now.

See how early detection may improve outcomes

Indications and Important Risk Information

Cologuard is intended for the qualitative detection of colorectal neoplasia associated DNA markers and for the presence of occult hemoglobin in human stool. A positive result may indicate the presence of colorectal cancer (CRC) or advanced adenoma (AA) and should be followed by colonoscopy. Cologuard is indicated to screen adults of either sex, 45 years or older, who are at typical average risk for CRC. Cologuard is not a replacement for diagnostic colonoscopy or surveillance colonoscopy in high-risk individuals.

Cologuard is not for high-risk individuals, including patients with a personal history of colorectal cancer and adenomas; have had a positive result from another colorectal cancer screening method within the last 6 months; have been diagnosed with a condition associated with high risk for colorectal cancer such as IBD, chronic ulcerative colitis, Crohn’s disease; or have a family history of colorectal cancer, or certain hereditary syndromes.

Positive Cologuard results should be referred to colonoscopy. A negative Cologuard test result does not guarantee absence of cancer or advanced adenoma. Following a negative result, patients should continue participating in a screening program at an interval and with a method appropriate for the individual patient.

False positives and false negatives do occur. In a clinical study, 13% of patients without colorectal cancer or advanced adenomas received a positive result (false positive) and 8% of patients with cancer received a negative result (false negative). The clinical validation study was conducted in patients 50 years of age and older. Cologuard performance in patients ages 45 to 49 years was estimated by sub-group analysis of near-age groups.

Cologuard performance when used for repeat testing has not been evaluated or established. Rx only.

*

Estimate based on approximately 150,000 cases per year over 365 days.

†

Estimate based on the US population aged 45 to 74 years as of 2018, adjusted for the reported rates of high-risk conditions and prior screening history for CRC.³

References: 1. Itzkowitz SH. Incremental advances in excremental cancer detection tests. J Natl Cancer Inst. 2009;101(18):1225-1227. doi:10.1093/jnci/djp273. 2. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7-33. doi.10.3322/caac21708. 3. Piscitello A, Edwards DK 5th. Estimating the screening-eligible population size, ages 45-74, at average risk to develop colorectal cancer in the United States. Cancer Prev Res. 2020;13(5):443-448. doi:10.1158/1940-6207.CAPR-19-0527. 4. Data & progress: colorectal cancer screening rates. National Colorectal Cancer Roundtable. Accessed March 9, 2022. https://nccrt.org/data-progress/. 5. Data on file. Exact Sciences Corporation. Madison, WI.

CRC Landscape
Early Detection
Impact of Choice
Barriers to CRC Screening

Clinical Offer
Cologuard vs FIT
Ease of Use
Appropriate Patients
National Guidelines

Coverage
Adherence Data
Specialized Support

How to Order
HCP Resources
HCP Media Library
Events

About Exact Sciences
Contact Us
Terms of Use
Privacy Policy
Do Not Sell My Info

EXACT SCIENCES CORPORATION | 5505 Endeavor Lane, Madison, WI 53719

Cologuard is a registered trademark of Exact Sciences Corporation in the U.S. and other countries. EpicCare^® and EpicCare^® Link^™ are trademarks of Epic Systems Corporation.

©2022 Exact Sciences Corporation. All rights reserved. US-CG-00203-August 2022